How is a multiphasic computed tomography urography performed for a patient with recent visible hematuria, including preparation, contrast administration, and the required imaging phases?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Multiphasic CT Urography Protocol for Hematuria Evaluation

Patient Preparation

Patients should be adequately hydrated (oral or intravenous fluids) 2-4 hours before the examination to ensure optimal opacification of the collecting system and ureters. 1, 2 No fasting is required, and maintaining hydration helps reduce the risk of contrast-induced nephropathy while improving image quality. 1

Screen for contraindications including renal insufficiency (serum creatinine/eGFR), contrast allergy history, pregnancy, and metformin use. 1 Patients with eGFR <30 mL/min/1.73m² or severe contrast allergies should be considered for alternative imaging such as MR urography. 1

Contrast Administration

Administer 100-150 mL of low-osmolar or iso-osmolar iodinated contrast intravenously at 2-4 mL/second. 2, 3 The contrast dose and injection rate are optimized to achieve adequate enhancement of both renal parenchyma and urothelial structures while minimizing nephrotoxicity risk. 1, 2

The risk of severe contrast reactions is extremely low per American College of Radiology criteria, though contrast-induced nephropathy occurs in up to 2% of general population patients and ≥20% of high-risk patients with congestive heart failure, diabetes, or chronic kidney disease. 1

Required Imaging Phases

Phase 1: Unenhanced (Non-Contrast) Scan

Acquire images from the kidneys through the bladder before contrast administration to detect renal calculi, which appear as high-density structures and are the most common cause of hematuria. 2, 4, 3 This phase is essential because contrast obscures calculi on subsequent phases. 2, 3

Unenhanced imaging also establishes baseline attenuation values for characterizing renal masses and detecting hemorrhage. 2, 3

Phase 2: Nephrographic Phase

Obtain images 80-100 seconds after contrast injection to capture peak renal parenchymal enhancement, which optimally demonstrates renal masses, renal cell carcinoma, and other parenchymal abnormalities. 2, 4, 3

All upper tract urothelial cell carcinomas are visible on the nephrographic phase, making this the most critical phase for detecting renal parenchymal disease. 4 This phase also provides excellent evaluation of other abdominal organs. 2, 3

Phase 3: Excretory (Delayed) Phase

Acquire thin-section images 5-15 minutes after contrast injection (timing adjusted based on renal function) from the kidneys through the bladder to visualize the contrast-opacified collecting systems, ureters, and bladder. 1, 2, 3

This delayed phase is mandatory for detecting urothelial lesions, filling defects, and upper tract transitional cell carcinoma, as it demonstrates the urinary tract distended with excreted contrast material. 1, 2, 3 The American College of Radiology specifically notes that high-resolution imaging during the excretory phase is required for adequate hematuria evaluation. 1

Some protocols include prone imaging during the excretory phase to improve ureteral distention and opacification, though this is optional. 2

Technical Parameters

Use multi-detector CT with thin collimation (≤3 mm) to allow multiplanar reconstructions and improved detection of small urothelial lesions. 2, 5 Coronal and sagittal reformations enhance visualization of the ureters and collecting systems. 2

The median effective radiation dose for standard 3-phase CT urography is 20-30 mSv, though this varies substantially (range 6-90 mSv) depending on scanner and protocol. 1 This represents one of the highest radiation exposures among common CT protocols, with an estimated lifetime attributable cancer risk of 4 cases per 1000 patients. 1

Diagnostic Performance

Multiphasic CT urography demonstrates 96% sensitivity and 99% specificity for detecting urothelial malignancy, with 99.6% accuracy for upper tract lesions and 97.2% accuracy for bladder lesions. 4, 5 This superior diagnostic performance makes CT urography the gold standard, replacing the previous combination of ultrasound and intravenous pyelography. 1, 5

CT urography permits comprehensive evaluation of hematuria patients in a single examination, detecting renal cell carcinoma, transitional cell carcinoma, and urolithiasis simultaneously. 2, 5, 3, 6

Clinical Context

Multi-detector CT urography with all three phases (unenhanced, nephrographic, excretory) had the most consistent and highest sensitivities and specificities for detecting lesions of the renal parenchyma and upper tracts in patients with asymptomatic microhematuria. 1 The American Urological Association gives this approach its highest recommendation for maximizing diagnostic certainty. 1

In a consecutive series of 771 hematuria patients, CT urography identified tumors/complex cysts in 18%, calculi in 9%, and other disease in 15%, with lesions found more frequently in visible hematuria (48%) versus non-visible hematuria (29%). 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Multi-detector row CT urography in the evaluation of hematuria.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2003

Research

Essentials of Computed Tomography Imaging of Hematuria.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2023

Research

CT urography for hematuria.

Nature reviews. Urology, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.